New trial
Spotlight
Phase 1 study of 111In-XYIMSR-01 radiotracer for clear cell renal cell carcinoma detection.
- Trial ID
- NCT07062549 on ClinicalTrials.gov
- Cancer type
- Kidney (RCC) Cancer
- Stage of research
- First-in-human
- Published in
- New in Oncology - Aug 1, 2025
An early-phase open-label study at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins evaluates the safety and tumor-targeting performance of 111In-XYIMSR-01 via SPECT/CT in participants with metastatic clear cell renal cell carcinoma. The trial aims to determine whether imaging can reliably detect tumor sites, potentially informing subsequent treatment options and future clinical strategies.
More in kidney cancer
-
Trial result · Oct 22, 2026 · NCT05805501
Tobemstomig (PD-1×LAG-3) ± tiragolumab (anti-TIGIT) + axitinib adds toxicity without PFS/ORR gain in 1L ccRCC -
New trial · Oct 15, 2026 · NCT07848295
Phase 1 BMS-986527 allogeneic CD70 CAR T-cell therapy is tested alone or with nivolumab or cabozantinib in clear cell RCC -
Trial result · Sep 24, 2026 · NCT04195750
Improving HRQoL Correlates With Longer PFS/OS in LITESPARK-005 -
Trial result · Sep 24, 2026 · NCT04987203
Tivozanib (VEGFR TKI) Beats Tivozanib+nivolumab in post-ICI mRCC, extending 2L PFS -
Trial result · Sep 24, 2026 · NCT05536141
Casdatifan (HIF-2α inhibitor) Monotherapy in Late-Line ccRCC Shows Class-On-Target Anemia/Hypoxia With Low Discontinuation